Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels-Reference-Cited by-同舟云学术

Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels

Published:2021-09-23 Issue:6 Volume:41 Page:694-696
ISSN:1533-712X
Container-title:Journal of Clinical Psychopharmacology
language:en
Short-container-title:J Clin Psychopharmacol

Author:

Cellini Lorenzo,De Donatis Domenico,Mercolini Laura,Panariello Fabio,De Ronchi Diana,Serretti Alessandro,Conca Andreas,Gaspari Davide,Giupponi Giancarlo,Zernig Gerald,Florio Vincenzo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference17 articles.

1. Efficacy and safety of long acting injectable atypical antipsychotics: a review;Curr Clin Pharmacol,2013

2. Clinical factors related to schizophrenia relapse;Int J Psychiatry Clin Pract,2016

3. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain;Int Clin Psychopharmacol,2021

4. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies;J Clin Psychiatry,2013

5. Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia;Neuropsychiatr Dis Treat,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics;The World Journal of Biological Psychiatry;2024-09

2. Debated issues in major psychoses;International Clinical Psychopharmacology;2023-05-26

3. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations;Expert Opinion on Drug Metabolism & Toxicology;2023-04-03

4. Interplay of environmental and clinical factors in psychiatric disorders;International Clinical Psychopharmacology;2023-03-06